Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari discusses the FDA’s award of orphan status and rare paediatric disease designation for the company’s DUNP19 technology.
Radiopharm Theranostics has the ambition to become a recognised leader in the development of radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs.
